Table 2.

Characteristics of Women With CIN2+ According to Number of Doses of Human Papillomavirus Vaccine Received ≥24 Months Before the Screening That Led to Diagnosis, HPV-IMPACT, United States, 2008–2014

Characteristic	0 Doses (n = 2,731)		Any Doses (n = 569)		P Valuea	1 Dose (n = 136)		2 Doses (n = 108)		3 Doses (n = 325)		P Valueb
	No.	%	No.	%		No.	%	No.	%	No.	%
Year of diagnosis					<0.001							<0.001
2008–2010	1,604	58.7	106	18.6		34	25.0	35	32.4	37	11.4
2011–2014	1,127	41.3	463	81.4		102	75.0	73	67.6	288	88.6
Age at diagnosis, years					<0.001							0.806
18–20	193	7.1	30	5.3		7	5.1	7	6.5	16	4.9
21–24	1,040	38.1	265	46.6		63	46.3	56	51.9	146	44.9
25–29	1,170	42.8	238	41.8		59	43.4	38	35.2	141	43.4
30–34	328	12.0	36	6.3		7	5.1	7	6.5	22	6.8
Birth cohort					<0.001							0.719
1979–1986	1,896	69.4	255	44.8		65	47.8	48	44.4	142	43.7
1987–1995	835	30.6	314	55.2		71	52.2	60	55.6	183	56.3
Age at vaccination, years												0.065
12–18			202	35.5		37	27.2	34	31.5	131	40.3
19–22			200	35.1		55	40.4	43	39.8	102	31.4
23–26			167	29.3		44	32.4	31	28.7	92	28.3
Diagnosis					0.043							0.903
CIN grade 2	1,483	54.3	338	59.4		84	61.8	61	56.5	193	59.4
CIN grade 2/3	393	14.4	82	14.4		19	14.0	15	13.9	48	14.8
CIN grade 3/AIS	855	31.3	149	26.2		33	24.3	32	29.6	84	25.8
Race/ethnicity					0.002							0.002
Non-Hispanic white	1,553	56.9	338	59.4		63	46.3	61	56.5	214	65.8
Non-Hispanic black	438	16.0	112	19.7		39	28.7	24	22.2	49	15.1
Hispanic	302	11.1	41	7.2		17	12.5	5	4.6	19	5.8
Other	235	8.6	53	9.3		11	8.1	12	11.1	30	9.2
Missing data	203	7.4	25	4.4		6	4.4	6	5.6	13	4.0
Surveillance site					0.003							<0.001
California	271	9.9	55	9.7		19	14.0	9	8.3	27	8.3
Connecticut	803	29.4	203	35.7		28	20.6	37	34.3	138	42.5
New York	843	30.9	181	31.8		40	29.4	37	34.3	104	32.0
Oregon	453	16.6	64	11.2		32	23.5	10	9.3	22	6.8
Tennessee	361	13.2	66	11.6		17	12.5	15	13.9	34	10.5
Type of health insurance					<0.001							<0.001
Private	1,466	53.7	361	63.4		66	48.5	63	58.3	232	71.4
Public	704	25.8	109	19.2		39	28.7	23	21.3	47	14.5
Other/none	177	6.5	33	5.8		10	7.4	6	5.6	17	5.2
Missing data	384	14.1	66	11.6		21	15.4	16	14.8	29	8.9

Abbreviations: AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; CIN2+, CIN grade 2, 2/3, or 3 and AIS; HPV, human papillomavirus; HPV-IMPACT, Human Papillomavirus Vaccine Impact Monitoring Project.

^aχ² test comparing 0 doses with any doses.

^bχ² test comparing 1, 2, and 3 doses.